Multiple Sclerosis

A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.

The study authors hope their findings inform future interventions whose goal is to minimize the comorbidity burden of adults with multiple sclerosis (MS), thereby improving their quality of life and ultimate health outcomes.

Compared with their peers receiving injectable treatments for their relapsing-remitting multiple sclerosis (RRMS), children who received newer disease-modifying therapies (DMTs) had improved scores on several measures of disease progression.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

The new study identified altered microRNA (miRNA) in gray matter lesions, which could provide a new important marker of multiple sclerosis (MS) progression.

Patient social cognition remained stable over 3 years, but its correlation with structural damage in the brain changed over time.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Confirmed disability progression is often used as a study endpoint to predict progression, but a new report says its predictive value may be overblown.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Using data from 2 independent cohorts, researchers identified a potential molecular biomarker for progressive multiple sclerosis (MS).

Progressive resistance training was shown to positively alter several measures of disease progression in the study cohort: fatty acid, phospholipid, and sex steroid metabolism.

Although knowledge is plentiful on disease state improvements for adult patients with multiple sclerosis (MS) following use of newer disease-modifying therapies, less is known about similar outcomes among patients with pediatric-onset MS (POMS).

New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against SARS-CoV-2, its causative virus, due to having fewer B cells.

Because real-world data are lacking on disease-modifying treatment (DMT) prescribing patterns for patients with multiple sclerosis (MS), a team of investigators wanted to make sure these individuals were receiving adequate care.

Risk of infection topped the list of concerns among patients with multiple sclerosis (MS) who altered their usual care routines during the COVID-19 pandemic.

In an abstract presented at this year’s American Academy of Neurology annual meeting, patients with multiple sclerosis (MS) taking ocrelizumab had less of an immune reaction to infection with SARS-CoV-2, the virus that causes COVID-19.

Compared with disease-modifying therapy (DMT), age, insurance status, and Hispanic ethnicity were shown to more accurately predict likelihood of COVID-19 and hospitalization from it among individuals with multiple sclerosis (MS).

An online tool developed to facilitate efficient patient-provider decisions on disease modifying drugs for multiple sclerosis (MS) ran into several challenges and warrants further study.

A prospective bicentric cohort study among individuals with relapsing-remitting multiple sclerosis (RRMS) showed that 32% developed at least 1 skin-related adverse reaction following cladribine administration.

The advent of both new diagnostic criteria and treatments have necessitated a reevaluation of fatigue among individuals who have multiple sclerosis, investigators say.

Because health literacy can have different meanings for patients with different diseases, this review aimed to crystalize a definition in patients with multiple sclerosis (MS) and emphasize its importance in care planning.

Among patients with multiple sclerosis, there is a 16% greater risk of infection, including for lower respiratory and herpes virus infections, after administration of fingolimod.

With most current therapies for patients with multiple sclerosis (MS) targeting disease progression, a recent review evaluated transcranial direct current stimulation’s ability to improve certain disease symptoms.

Investigators aimed to close the knowledge gap on interindividual variability in cognitive evaluation outcomes by considering both cognitive impairment and mood disorders to better prediction accuracy.

With many patients with multiple sclerosis (MS) increasingly turning to herbal drugs and supplements to treat their disease, for which there is no cure, a recent review evaluated the safety of these alternative therapies.